About the Study

Allogeneic Hematopoietic Cell Transplant (HCT): A study to see if letermovir prevents Cytomegalovirus infection in patients after a stem cell transplant

This study is for children: • 2-17 years old • With a planned allogeneic hematopoietic cell transplant (HCT) The study involves adding the drug letermovir to standard therapy after HCT. The goal of this study is to determine whether taking letermovir will reduce the likelihood of infection with Cytomegalovirus (CMV) after HCT.

Interested in learning more?

Full Study Name: ACCL1932 - Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell Transplantation